



Spontaneous Suprachoroidal Hemorrhage in a Patient on Apixaban: A Case Report

Faisal Alqahtani¹, Yahya A Alyahya^{2,*}, Hend AlSafran¹ and Jinan Alhamad³

¹Ophthalmology Department, King Khalid Eye Specialist Hospital, Riyadh, Saudi Arabia

²Ophthalmology Department, King Saud University, College of Medicine, Riyadh, Saudi Arabia

³Ophthalmology Department, Dhahran Eye Specialist Hospital, Dhahran, Saudi Arabia

Abstract:

Introduction: We, herein, present a rare case report evaluating an elderly patient who developed spontaneous suprachoroidal hemorrhage (SSCH) while using apixaban (direct oral anticoagulant agent).

Case Presentation: An 82-year-old man with a known history of hypertension and atrial fibrillation on apixaban presented with a sudden onset of flashes, floaters, and a temporal curtain-like visual field defect in his right eye. He had no preceding history of trauma or recent ocular surgery. Ophthalmological examination revealed two large elevated grayish choroidal lesions with associated exudative retinal detachment. Ultrasonography and wide-field fluorescein angiography confirmed the diagnosis of SSCH. The patient was managed with topical steroids and cyclopentolate. One month later, the vision improved, and the hemorrhage showed signs of resolution.

Discussion: Direct oral anticoagulant agents (DOACs) are safer and carry a lower risk of major bleeding events compared to the traditionally used antiplatelet therapy and thrombolytic agents; however, patients may still be at risk of spontaneous suprachoroidal hemorrhage.

Conclusion: Spontaneous suprachoroidal hemorrhage can very rarely occur with the use of DOACs, with only two cases reported in the literature, and here, we present a case of SSCH in a patient while using apixaban.

Keywords: Suprachoroidal hemorrhage, Apixaban, Anticoagulant, Peripheral exudative hemorrhagic chorioretinopathy, Antiplatelets, DOACs.

© 2026 The Author(s). Published by Bentham Open.

This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: <https://creativecommons.org/licenses/by/4.0/legalcode>. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



Received: July 24, 2025

Revised: September 02, 2025

Accepted: September 16, 2025

Published: January 19, 2026



Send Orders for Reprints to
reprints@benthamscience.net

1. INTRODUCTION

Suprachoroidal hemorrhage (SCH) is a fulminatory accumulation of blood within the suprachoroidal space [1]. It is considered an uncommon, serious complication, and is usually associated with ocular surgery or trauma [2, 3]. Patients who develop this condition usually present with an

acute and sudden decrease in vision, acute angle closure glaucoma, and have a poor visual prognosis [3]. Although SCH can occur spontaneously, it is considered a very rare occurrence [4]. Ocular risk factors that have been associated with suprachoroidal hemorrhage include age-related macular degeneration, glaucoma, high myopia, and aphakia [5]. Spontaneous suprachoroidal hemorrhage has

*Address correspondence to this author at the Ophthalmology Department, King Saud University, College of Medicine, Riyadh, Saudi Arabia; Tel: 966550138808; E-mail: Dr.Yahya012@gmail.com

Cite as: Alqahtani F, Alyahya Y, AlSafran H, Alhamad J. Spontaneous Suprachoroidal Hemorrhage in a Patient on Apixaban: A Case Report. Open Ophthalmol J. 2026; 20: e18743641427164. <http://dx.doi.org/10.2174/0118743641427164251008052645>

been reported mainly with older anticoagulants (*e.g.*, warfarin, low-molecular-weight heparin), antiplatelet agents, or thrombolytics [1-3]. Newer DOACs, such as apixaban, are known to carry a better safety profile and significantly lower risk of bleeding compared to the aforementioned agents [6-8]. However, we have, herein, reported a case of SSCH associated with the direct oral anticoagulant agent apixaban. Of note, the hemorrhage was localized and limited, simulating the clinical appearance of choroidal melanoma.

2. CASE REPORT

An 82-year-old man presented to the emergency room complaining of a sudden onset of flashes, floaters, and a temporal visual field defect in the right eye that started one day before presentation. The patient denied any recent history of eye surgery or trauma. His past medical history was positive for hypertension, chronic atrial fibrillation (on apixaban anticoagulant), and a cerebral vascular accident. His past ophthalmic history was positive for cataract surgery in both eyes, performed 20 years back, and a successful penetrating keratoplasty in the right eye, performed 2 years back, for a corneal scar due to trachoma. Ophthalmological examination of the right eye showed a visual acuity of 20/400, a clear sutureless corneal graft, a deep and quiet anterior chamber, and an intraocular pressure (IOP) of 10 mmHg. Fundoscopy of the right eye revealed two grayish choroidal lesions, a larger one localized nasally and a smaller one superotemporally, both of which were associated with subretinal fluid (Fig. 1A). An examination of the left eye demonstrated a visual acuity of 20/200, Herbert pits with a corneal scar, and an otherwise unremarkable anterior segment and fundus examination. Ocular posterior segment ultrasonography (US)

examination of the right eye was consistent with findings suggestive of bullous hemorrhagic choroidal detachments associated with minimal subretinal fluid (Fig. 1B). The patient was managed with close observation and started on topical steroids and cyclopentolate for the right eye. One month later, his vision improved to 20/200 in the right eye, and the SCH showed signs of resolution. Ocular posterior segment ultrasonography (US) of the right eye after 1 month showed a shallow SCH inferonasally with a stable SCH in the superotemporal quadrant of the retina (Fig. 2).

3. DISCUSSION

Several cases of spontaneous suprachoroidal hemorrhage (SSCH) have been reported in the literature [2]. This rare entity has been described mainly in patients on anticoagulants (namely warfarin and low-molecular-weight heparin), antiplatelets (such as aspirin and clopidogrel), and thrombolytic therapy with tissue plasminogen activator (tPA) or streptokinase. In the majority of cases in which patients are on anticoagulation/antiplatelet/thrombolytic therapy, another associated risk factor is usually present, such as advanced age, systemic hypertension, atherosclerosis, diabetes mellitus, chronic renal disease, cardiovascular/cerebrovascular disease, preceding Valsalva maneuvers, and/or age-related macular degeneration, which is the most commonly associated ocular risk factor [9-13].

In this case report, we have described the case of a patient who presented with SSCH while on direct oral anticoagulant (DOAC) apixaban. In the literature, there are only two cases of SSCH associated with DOAC medication use, specifically rivaroxaban and dabigatran [9]. Additional risk factors that may have likely contributed to our patient's spontaneous hemorrhage included old age, systemic hypertension, and cardiovascular disease.




Fig. (1). Wide-field colored fundus photograph of the right eye showing large grayish choroidal lesions localized nasally (white arrows) with minimal subretinal fluid (A). Ocular posterior segment ultrasonography (US) examination showed bullous hemorrhagic choroidal detachment along the nasal arcade (circle) with minimal subretinal fluid (B).



Fig. (2). Ocular posterior segment ultrasonography (US) examination showed shallow choroidal detachment nasally (circle) and inferiorly, with no subretinal fluid.

Apixaban is an oral drug that works as a direct factor Xa inhibitor, inhibiting both free and clot-bound factor Xa, and has been approved in various thromboembolic conditions, including atrial fibrillation, which was the indication for use in our patient [7]. Over the last decade, direct oral anticoagulants (DOACs), such as apixaban, dabigatran, edoxaban, and rivaroxaban, have become widely available and are replacing the traditional vitamin K antagonists (VKAs), such as warfarin, in patients at risk of thromboembolic events. This shift in practice occurred after randomized control trials and observational studies confirmed that these newer anticoagulants are both efficacious and safer than the traditionally used VKAs, demonstrating a significantly lower rate of major bleeding events in patients on these medications [6, 7, 8]. However, as more patients have started using these medications, the literature has recently been seeing more reports describing bleeding events in patients on these medications. Apixaban has been reported recently in multiple case reports to be associated with life-threatening spontaneous hemorrhagic pericardial effusion leading to significant morbidity and mortality [14-20]. Thus, it is important for physicians to remain aware that the risk of bleeding with DOACs, though small, is still present.

In our case report, our patient presented with a localized and limited SCH that did not progress. The hemorrhage was resolved without permanent vision loss and/or vision-threatening complications, such as acute angle closure glaucoma. Our patient also did not require any surgical intervention. This is in contrast to the majority of reported cases of SSCH associated with the use of traditional anticoagulant medications, particularly warfarin and low-molecular-weight heparin, antiplatelet therapy, or thrombolytic agents; many of these cases have presented with severe and permanent vision loss due to

massive SCHs, sometimes complicated with acute angle closure glaucoma and often requiring surgical intervention [19, 20]. The limited and self-resolving nature of hemorrhage in our patient was consistent with the higher safety profile and lower associated risk of bleeding events associated with DOACs compared to older anticoagulants, antiplatelets, and thrombolytic therapy.

The localized and limited nature of SCH in our patient was confused with the characteristic appearance of choroidal melanoma as well as peripheral exudative hemorrhagic chorioretinopathy (PEHCR). A localized, dome-shaped lesion, being gray-brown in color and presenting in a patient of old age complaining of a visual field defect associated with photopsia, raises suspicion for both choroidal melanoma and PEHCR. This confusion has been previously reported in the literature. Three cases were reported by Morgan *et al.* [21]. In a study by Shields *et al.*, a review of over 12,000 patients who were referred to a tertiary referral center as cases of choroidal melanoma demonstrated 2% of pseudo-melanomas to be cases of hemorrhagic choroidal detachment. In the same study, PEHCR was diagnosed in 8% of pseudo-melanoma cases [22]. Fung *et al.* further reported several cases of SCH referred to a tertiary referral center as cases of choroidal melanoma [23]. Two cases of cough-induced SCH and a case of SSCH in a patient with idiopathic thrombocytopenic purpura simulating choroidal melanomas have also been reported in the literature [15, 24].

The work-up in our patient was aimed initially at ruling out choroidal melanoma (a life- and vision-threatening condition), followed by PEHCR (a potentially vision-threatening condition sometimes requiring prompt treatment) [25, 26]. Based on multimodal imaging (particularly ultrasonography and wide-field fluorescein angiography), a diagnosis of SCH was confidently made in our patient. B-scan ultrasonography of the lesion showed a localized bullous hemorrhagic choroidal detachment that was hyperechoic, with minimal subretinal fluid, and no choroidal excavation. In contrast, choroidal melanomas demonstrate a generally acoustically hollow lesion on B-scan, may present with a collar button configuration, may be associated with more significant subretinal fluid, and may demonstrate choroidal excavation [24]. PEHCR lesions may appear dome- or plateau-shaped and demonstrate variable echogenicity on B-scan, resembling SCH [25, 26]. Therefore, B-scan ultrasonography was followed by wide-field fluorescein angiography, which showed only blockage, no vascularity (ruling out choroidal melanoma), and no hyper- or hypo-fluorescence suggestive of areas of RPE atrophy or hyperplasia [25].

Associated risk factors should be controlled to avoid progressive or recurrent hemorrhage; this may include controlling blood pressure and temporarily stopping or reversing anticoagulation therapy if the patient's systemic medical condition permits under the care of an internist/ cardiologist/hematologist [2-4]. In our patient, the hemorrhage resolved with conservative management, observation, and temporary discontinuation of anti-coagulation therapy.

CONCLUSION

DOACs, such as apixaban, are a relatively new class of anticoagulants. These medications are safer and carry a lower risk of major bleeding events compared to the traditionally used VKAs, antiplatelet therapy, and thrombolytic agents. Nevertheless, patients may still be at risk of spontaneous bleeding. When bleeding manifests in the eye due to a spontaneous suprachoroidal hemorrhage (SSCH), it may carry a less severe course and present with a distinct clinical picture simulating choroidal melanoma and PEHCR. Therefore, an appropriate work-up with B-scan ultrasonography and fluorescein angiography (FFA) is indicated to rule out these more serious conditions.

AUTHORS' CONTRIBUTIONS

The authors confirm their contribution to the paper as follows: J.A.: Data collection; Y.A., F.A.: Drafting of the manuscript; H.A.: Writing, review, and editing. All authors reviewed the results and approved the final version of the manuscript.

LIST OF ABBREVIATIONS

SCH	= Suprachoroidal hemorrhage
SSCH	= Spontaneous suprachoroidal hemorrhage
PEHCR	= Peripheral exudative hemorrhagic chorioretinopathy
DOACs	= Direct oral anticoagulants
IOP	= Intraocular pressure
TPA	= Tissue plasminogen activator
VKAs	= Vitamin K antagonists
US	= Ultrasonography

ETHICS APPROVAL AND CONSENT TO PARTICIPATE

This study was approved by King Khalid Eye Specialist Hospital, Riyadh, Saudi Arabia, with Approval No.: RD/26001/IRB/0871-25.

HUMAN AND ANIMAL RIGHTS

All human research procedures followed were in accordance with the ethical standards of the committee responsible for human experimentation (institutional and national), and with the Helsinki Declaration of 1975, as revised in 2013.

CONSENT FOR PUBLICATION

Written informed consent was obtained from the patient for publication of this article and any accompanying images.

STANDARDS OF REPORTING

CARE guidelines were followed.

AVAILABILITY OF DATA AND MATERIALS

All the data and supporting information are provided within the article.

FUNDING

None.

CONFLICT OF INTEREST

The authors declare no conflict of interest, financial or otherwise.

ACKNOWLEDGEMENTS

Declared none.

REFERENCES

- Chen YY, Chen YY, Sheu SJ. Spontaneous suprachoroidal hemorrhage associated with age-related macular degeneration and anticoagulation therapy. *J Chin Med Assoc* 2009; 72(7): 385-7. [http://dx.doi.org/10.1016/S1726-4901\(09\)70393-4](http://dx.doi.org/10.1016/S1726-4901(09)70393-4) PMID: 19581147
- Akkan Aydoğmuş FS, Serdar K, Kalayci D, Çelik A. Spontaneous suprachoroidal hemorrhage associated with iatrogenic coagulopathy. *Retin Cases Brief Rep* 2019; 13(2): 174-5. <http://dx.doi.org/10.1097/ICB.0000000000000554> PMID: 28272191
- Hsiao SF, Shih MH, Huang FC. Spontaneous suprachoroidal hemorrhage: Case report and review of the literature. *Taiwan J Ophthalmol* 2016; 6(1): 36-41. <http://dx.doi.org/10.1016/j.tjo.2014.10.008> PMID: 29018708
- De Marco R, Aurilia P, Mele A. Massive spontaneous choroidal hemorrhage in a patient with chronic renal failure and coronary artery disease treated with Plavix. *Eur J Ophthalmol* 2009; 19(5): 883-6. <http://dx.doi.org/10.1177/112067210901900534> PMID: 19787616
- Tripathy K, Chawla R, Mutha V, Selvan H. Spontaneous suprachoroidal haemorrhage with exudative retinal detachment in pregnancy-induced hypertension. *BMJ Case Rep* 2018; 2018: bcr-2017-223907. <http://dx.doi.org/10.1136/bcr-2017-223907> PMID: 29523618
- Caldeira D, Rodrigues FB, Barra M, et al. Non-vitamin K antagonist oral anticoagulants and major bleeding-related fatality in patients with atrial fibrillation and venous thromboembolism: A systematic review and meta-analysis. *Heart* 2015; 101(15): 1204-11. <http://dx.doi.org/10.1136/heartjnl-2015-307489> PMID: 26037103
- Almutairi AR, Zhou L, Gellad WF, et al. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants for atrial fibrillation and venous thromboembolism: A systematic review and meta-analyses. *Clin Ther* 2017; 39(7): 1456-78. <http://dx.doi.org/10.1016/j.clinthera.2017.05.358> PMID: 28668628
- McMahon B, Kwaan H. The new or non-vitamin K antagonist oral anticoagulants: What have we learned since their debut. *Semin Thromb Hemost* 2015; 41(2): 188-94. <http://dx.doi.org/10.1055/s-0035-1544159> PMID: 25682082
- Atia R, Bonnel S, Vallos M, Laroche L, Borderie V, Bouheraoua N. [Spontaneous choroidal hemorrhage associated with novel oral anticoagulants: A report of two cases and literature review]. *J Fr Ophthalmol* 2018; 41(8): 767-72. <http://dx.doi.org/10.1016/j.jfo.2018.01.007> PMID: 30213607
- Mohan S, Sadeghi E, Mohan M, Iannetta D, Chhablani J. Suprachoroidal hemorrhage. *Ophthalmologica* 2023; 246(5-6): 255-77. <http://dx.doi.org/10.1159/000533937> PMID: 37660688
- Collon S, Teske M, Simonett J. Bilateral spontaneous suprachoroidal hemorrhage after systemic tissue plasminogen activator. *Ophthalmol Retina* 2022; 6(6): 519. <http://dx.doi.org/10.1016/j.oret.2022.03.023> PMID: 35680237
- Shan H, Wu X, Guo H. Spontaneous suprachoroidal and orbital hemorrhage in an older woman associated with prophylactic antiplatelet therapy: A case report and literature review. *Heliyon* 2022; 8(11): e11511.

<http://dx.doi.org/10.1016/j.heliyon.2022.e11511> PMID: 36411881

[13] Zahid S, Dansingani KK, Fisher Y. Optical coherence tomography evaluation of valsalva-induced suprachoroidal hemorrhage. *Ophthalmic Surg Lasers Imaging Retina* 2016; 47(7): 674-6. <http://dx.doi.org/10.3928/23258160-20160707-11> PMID: 27434901

[14] Cinelli M, Uddin A, Duka I, et al. Spontaneous hemorrhagic pericardial and pleural effusion in a patient receiving apixaban. *Cardiol Res* 2019; 10(4): 249-52. <http://dx.doi.org/10.14740/cr902> PMID: 31413784

[15] Nasir SA, Babu Pokhrel N, Baig A. Hemorrhagic pericardial effusion from apixaban use: Case report and literature review. *Cureus* 2022; 14(10): e30021. <http://dx.doi.org/10.7759/cureus.30021> PMID: 36381894

[16] Latif R, Aloqaily M, Rabadi A, et al. Apixaban-induced hemopericardium in a post-TAVR patient: A case report highlighting diagnostic and management challenges. *Am J Case Rep* 2024; 25: e944173. <http://dx.doi.org/10.12659/AJCR.944173> PMID: 39058665

[17] Trivedi D, Lorenzana AM, Bronchard K, Reddy B. Spontaneous hemorrhagic pericardial effusion as a consequence of apixaban utilization for new-onset atrial fibrillation. *Cureus* 2024; 16(3): e56510. <http://dx.doi.org/10.7759/cureus.56510> PMID: 38646361

[18] Ambat J, Patel S, Pathak PR, et al. Apixaban-induced spontaneous hemorrhagic cardiac tamponade. *Cureus* 2024; 16(3): e55476. <http://dx.doi.org/10.7759/cureus.55476> PMID: 38571853

[19] Khan A, Mastenbrook J, Bauler L. Pain in the hip: Spontaneous retroperitoneal hemorrhage in an elderly patient on apixaban. *Am J Emerg Med* 2020; 38(5): 1046.e1-3. <http://dx.doi.org/10.1016/j.ajem.2019.12.049> PMID: 31932125

[20] Janke A, Ikejiani S, Mize C. Spontaneous splenic hemorrhage in a patient on apixaban. *Am J Emerg Med* 2020; 38(5): 1044.e1-2. <http://dx.doi.org/10.1016/j.ajem.2019.12.006> PMID: 31932128

[21] Morgan CM, Gragoudas ES. Limited choroidal hemorrhage mistaken for a choroidal melanoma. *Ophthalmology* 1987; 94(1): 41-6. [http://dx.doi.org/10.1016/S0161-6420\(87\)33509-2](http://dx.doi.org/10.1016/S0161-6420(87)33509-2) PMID: 3550566

[22] Shields JA, Mashayekhi A, Ra S, Shields CL. Pseudomelanomas of the posterior uveal tract: The 2006 Taylor R. Smith Lecture. *Retina* 2005; 25(6): 767-71. <http://dx.doi.org/10.1097/00006982-200509000-00013> PMID: 16141866

[23] Fung AT, Fulco EM, Shields CL, Shields JA. Choroidal hemorrhage simulating choroidal melanoma. *Retina* 2013; 33(8): 1726-8. <http://dx.doi.org/10.1097/IAE.0b013e31828dac9d> PMID: 23591536

[24] Marous CL, Sioufi K, Shields CL, Mashayekhi A, Shields JA. COUGHING-INDUCED SUPRACHOROIDAL HEMORRHAGE SIMULATING MELANOMA IN TWO CASES. *Retin Cases Brief Rep* 2018; 12(4): 336-41. <http://dx.doi.org/10.1097/ICB.0000000000000502> PMID: 27893592

[25] Vandefonteyne S, Caujolle JP, Rosier L, et al. Diagnosis and treatment of peripheral exudative haemorrhagic chorioretinopathy. *Br J Ophthalmol* 2020; 104(6): 874-8. <http://dx.doi.org/10.1136/bjophthalmol-2018-313307> PMID: 31645320

[26] Elwood KF, Richards PJ, Schildroth KR, Mitiitelu M. Peripheral Exudative Hemorrhagic Chorioretinopathy (PEHCR): Diagnostic and Therapeutic Challenges. *Medicina (Kaunas)* 2023; 59(9): 1507. <http://dx.doi.org/10.3390/medicina59091507> PMID: 37763626